İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
Stryker Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $114.2B | |
|---|---|---|
| P/E (forward) | 16.5x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.11B | $18.45B | $20.50B | $22.60B | $25.12B | +10.1% |
| Gross profit | $10.97B | $11.58B | $13.06B | $14.44B | $16.07B | +10.0% |
| Operating income | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B | +17.3% |
| Net income | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B | +13.0% |
| EPS (diluted) | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 | +12.7% |
| EBITDA | $3.61B | $4.02B | $5.06B | $6.01B | $6.31B | +15.0% |
| R&D | $1.24B | $1.45B | $1.39B | $1.47B | $1.62B | +7.1% |
| SG&A | $6.43B | $6.39B | $7.11B | $7.69B | $8.65B | +7.7% |
Recent company headlines from major financial publishers.
Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.
Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.6% | $346 | $357 | $368 | $381 | $395 |
| 8.1% | $321 | $329 | $338 | $348 | $359 |
| 8.6% | $299 | $306 | $313 | $321 | $330 |
| 9.1% | $280 | $286 | $292 | $299 | $306 |
| 9.6% | $264 | $269 | $274 | $279 | $285 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |